Zacks Research Brokers Decrease Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at Zacks Research lowered their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of ($0.26) per share for the quarter, down from their prior forecast of ($0.25). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics' Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.37) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, hitting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The business had revenue of $73.69 million during the quarter, compared to analysts' expectations of $72.17 million.

IOVA has been the subject of a number of other reports. Robert W. Baird dropped their price target on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a report on Friday, February 28th. The Goldman Sachs Group cut their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Finally, Truist Financial cut their target price on Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Iovance Biotherapeutics has an average rating of "Moderate Buy" and a consensus target price of $20.25.

Remove Ads

Iovance Biotherapeutics Trading Up 5.5 %

Iovance Biotherapeutics stock traded up $0.19 during midday trading on Monday, hitting $3.63. The stock had a trading volume of 7,414,042 shares, compared to its average volume of 6,999,801. Iovance Biotherapeutics has a 52-week low of $3.33 and a 52-week high of $15.18. The company has a market capitalization of $1.19 billion, a PE ratio of -2.44 and a beta of 0.93. The firm's fifty day moving average is $4.98 and its two-hundred day moving average is $7.63.

Hedge Funds Weigh In On Iovance Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at approximately $515,000. Jennison Associates LLC purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at $493,000. Barclays PLC lifted its position in Iovance Biotherapeutics by 118.8% during the third quarter. Barclays PLC now owns 604,584 shares of the biotechnology company's stock valued at $5,677,000 after purchasing an additional 328,284 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Iovance Biotherapeutics by 59.0% in the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company's stock worth $37,872,000 after buying an additional 1,496,941 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Iovance Biotherapeutics in the 3rd quarter worth about $920,000. Hedge funds and other institutional investors own 77.03% of the company's stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.